Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials
Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding round. The financing was led by New York-based global venture capital and private equity firm Insight Partners with participation from new investor Radical Ventures, as well as all of the company’s existing investors including 8VC, DCVC, DCVC Bio and Mubadala Capital Ventures. Through its investment, Dylan Morris, Managing Director, Insight Partners, has joined the Unlearn Board of Directors.
Comments are closed.